NEFL and neuropathy: The APOLLO and phase 2 OLE investigations have demonstrated that Patisiran therapy significantly diminishes NfL concentrations and enhances neuropathy outcomes as evaluated by mNIS+7 and QOL measures in contrast to initial assessments (21).